Co-amplification of MET with METΔex14 is associated with stage IV NSCLC and resulted in a 24-fold increase in MET expression compared with a three-fold increase in expression with METΔex14 alone [44],[18]). This evidence concerns the gene MET and non-small cell lung carcinoma.